보툴리눔톡신(보톡스) CDMO 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 서비스별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Botulinum Toxin CDMO Market Summary

The global botulinum toxin CDMO market size was estimated at USD 2.5 billion in 2025 and is projected to reach USD 5.8 billion by 2033, growing at a CAGR of 11.5% from 2026 to 2033. The industry is expected to grow due to strong demand from end users, expanding therapeutic applications, and ongoing advancements in biopharmaceutical technologies.

Besides, some other factors contributing to the market growth are the rising popularity of minimally invasive aesthetic procedures, growing consumer awareness, increased social acceptance, and an aging population seeking effective anti-aging solutions. In addition, the expanding range of therapeutic uses, including treatments for chronic migraine, spasticity, and overactive bladder, is expected to broaden the patient base and increase demand for specialized manufacturing capabilities.

In addition, technological advancements are expected to drive the market growth by boosting efficiency, scalability, and product performance. Besides, developments in formulation, such as extended-duration botulinum toxin variants and protein-free compositions, are enhancing efficacy and minimizing immunogenicity risks. Advanced delivery systems, such as microneedles and precision injection devices, improve treatment outcomes and enhance patient safety. The rise of automation, digital manufacturing technologies, and single-use systems is facilitating more consistent processes and cost reductions.

Moreover, regulatory frameworks play a crucial role in shaping the market landscape. As botulinum toxin products are mostly considered biologics, they are required to adhere to strict compliance with quality, safety, and clinical standards. Increasing regulatory scrutiny and enhanced traceability requirements are prompting CDMOs to invest in robust quality management systems and meticulous documentation practices. The expansion of regulatory approvals for various indications supports broader commercialization and long-term market growth.

Global Botulinum Toxin CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global botulinum toxin CDMO market report based on product, service, application, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Type A Botulinum Toxin
• Type B Botulinum Toxin
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Contract Development
  • Formulation Development
  • Process Development and Scale-Up
  • Analytical and Testing Services
  • Others
• Contract Manufacturing
  • Clinical Manufacturing
  • Commercial Manufacturing
• Packaging & Labelling
• Regulatory Affairs
• Supply Chain & Logistics
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Therapeutic
• Aesthetic
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical Companies
• Biotechnology Companies
• Aesthetic & Specialty Companies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Service
  • 1.2.3. Application
  • 1.2.4. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Botton-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Botulinum Toxin CDMO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Botulinum Toxin CDMO Market: Product Estimates & Trend Analysis

• 4.1. Botulinum Toxin CDMO Market, By Product: Segment Dashboard
• 4.2. Botulinum Toxin CDMO Market, By Product: Movement Analysis
• 4.3. Botulinum Toxin CDMO Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
• 4.4. Type A Botulinum Toxin
  • 4.4.1. Type A Botulinum Toxin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Type B Botulinum Toxin
  • 4.5.1. Type B Botulinum Toxin Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Botulinum Toxin CDMO Market: Service Estimates & Trend Analysis

• 5.1. Botulinum Toxin CDMO Market, By Service: Segment Dashboard
• 5.2. Botulinum Toxin CDMO Market, By Service: Movement Analysis
• 5.3. Botulinum Toxin CDMO Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 5.4. Contract Development
  • 5.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Formulation Development
    • 5.4.2.1. Formulation Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Process Development and Scale-Up
    • 5.4.3.1. Process Development and Scale-Up Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.4. Analytical and Testing Services
    • 5.4.4.1. Analytical and Testing Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.5. Others
    • 5.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Contract Manufacturing
  • 5.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Clinical Manufacturing
    • 5.5.2.1. Clinical Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Commercial Manufacturing
    • 5.5.3.1. Commercial Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Packaging & Labelling
  • 5.6.1. Packaging & Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Regulatory Affairs
  • 5.7.1. Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Supply Chain & Logistics
  • 5.8.1. Supply Chain & Logistics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Botulinum Toxin CDMO Market: Application Estimates & Trend Analysis

• 6.1. Botulinum Toxin CDMO Market, By Application: Segment Dashboard
• 6.2. Botulinum Toxin CDMO Market, By Application: Movement Analysis
• 6.3. Botulinum Toxin CDMO Market Estimates & Forecasts, By Application, 2021 - 2033 (USD Million)
• 6.4. Therapeutic
  • 6.4.1. Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Aesthetic
  • 6.5.1. Aesthetic Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Botulinum Toxin CDMO Market: End Use Estimates & Trend Analysis

• 7.1. Botulinum Toxin CDMO Market, By End Use: Segment Dashboard
• 7.2. Botulinum Toxin CDMO Market, By End Use: Movement Analysis
• 7.3. Botulinum Toxin CDMO Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
• 7.4. Pharmaceutical Companies
  • 7.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Biotechnology Companies
  • 7.5.1. Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Aesthetic & Specialty Companies
  • 7.6.1. Aesthetic & Specialty Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Botulinum Toxin CDMO Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2025 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. Saudi Arabia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Qatar
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Oman
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Key Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Lonza Group
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Thermo Fisher Scientific (Patheon)
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Vetter Pharma-Fertigung GmbH & Co. KG
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Recipharm AB
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Cenexi Group
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Grand River Aseptic Manufacturing
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Pharmaron
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. WuXi Biologics
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Samsung Biologics
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Catalent, Inc.
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Boehringer Ingelheim BioXcellence
    • 9.3.11.1. Company Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. Fujifilm Diosynth Biotechnologies
    • 9.3.12.1. Company Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Service Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. Cambrex Corporation
    • 9.3.13.1. Company Overview
    • 9.3.13.2. Financial Performance
    • 9.3.13.3. Service Benchmarking
    • 9.3.13.4. Strategic Initiatives
  • 9.3.14. Apeloa Pharmaceutical Co., Ltd.
    • 9.3.14.1. Company Overview
    • 9.3.14.2. Financial Performance
    • 9.3.14.3. Service Benchmarking
    • 9.3.14.4. Strategic Initiatives
  • 9.3.15. Hikal Ltd
    • 9.3.15.1. Company Overview
    • 9.3.15.2. Financial Performance
    • 9.3.15.3. Service Benchmarking
    • 9.3.15.4. Strategic Initiatives